TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Fennec Pharmaceuticals ( (TSE:FRX) ) just unveiled an update.
Fennec Pharmaceuticals announced the successful closing of a non-brokered private offering of common shares in Canada, raising approximately US$5,025,000. This move is part of their strategy to strengthen their financial position and support the commercialization of their flagship product, PEDMARK®. The offering was conducted under specific Canadian securities exemptions, allowing the shares to be free from a hold period, thus enhancing liquidity. This development is expected to bolster Fennec’s market presence and operational capabilities, potentially benefiting stakeholders by increasing the company’s resources for further growth and expansion.
The most recent analyst rating on (TSE:FRX) stock is a Buy with a C$13.00 price target. To see the full list of analyst forecasts on Fennec Pharmaceuticals stock, see the TSE:FRX Stock Forecast page.
Spark’s Take on TSE:FRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:FRX is a Neutral.
Fennec Pharmaceuticals shows strong revenue growth and improved cash flow, key for its industry. However, profitability issues and a weak balance sheet weigh down the score. Technical indicators and valuation reflect mixed signals, while positive earnings call sentiments provide some optimism. Addressing financial challenges will be crucial for future performance.
To see Spark’s full report on TSE:FRX stock, click here.
More about Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on combating ototoxicity in cancer patients undergoing cisplatin-based chemotherapy. The company is primarily engaged in the commercialization of PEDMARK®, a product designed to reduce the risk of platinum-induced ototoxicity, which has received regulatory approvals in the U.S., Europe, and the U.K. Fennec has also partnered with Norgine Pharmaceuticals Ltd. for the commercialization of PEDMARQSI® in Europe, the U.K., Australia, and New Zealand, and holds patents for PEDMARK® valid until 2039.
Average Trading Volume: 1,334
Technical Sentiment Signal: Buy
Current Market Cap: C$313.5M
See more data about FRX stock on TipRanks’ Stock Analysis page.